


## ASPER-29

Cat. No.:	HY-152210
CAS No.:	2630388-03-1
Molecular Formula:	C <sub>31</sub> H <sub>29</sub> BrN <sub>2</sub> O <sub>3</sub> S
Molecular Weight:	621.54
Target:	Cathepsin
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	ASPER-29 is Asperphenamate HY-129578 analog. ASPER-29 also is a dual cathepsin L and S inhibitor with IC <sub>50</sub> value of 6.03 μM and 5.02 μM, respectively. ASPER-29 can be used for the research of the migration and invasion of cancer <sup>[1]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	cathepsin L 6.03 μM (IC <sub>50</sub> )	cathepsin S 5.02 μM (IC <sub>50</sub> )
<b>In Vitro</b>	ASPER-29 has dual Cat L and S inhibitory potency with IC <sub>50</sub> value of 6.03 μM and 5.02 μM, respectively <sup>[1]</sup> . ASPER-29 shows a definite antimetastatic effect on pancreatic cancer BxPC-3 and PANC-1 cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Haoqiang Huang, et al. Design and synthesis of dual cathepsin L and S inhibitors and antimetastatic activity evaluation in pancreatic cancer cells. *Bioorg Med Chem Lett.* 2022 Nov 23;80:129087.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA